Tutti gli studi
Iscrizione su invitoOSSERVAZIONALE

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

This study is gathering information about a medicine called Esperoct® (turoctocog alfa pegol (N8-GP)). It's for males of all ages who have haemophilia A and are already taking Esperoct® to prevent bleeds. The aim is to see how well the medicine works over a long time and if there are any side effects. You'll get the same care you normally would, and your doctor will ask about your health and any bleeds since your last visit. You'll also keep a diary of your bleeds. The study will last about 5 to 7 years. You can choose to leave the study at any time, and it won't affect your medical care.

A colpo d'occhio

Stato
Iscrizione su invito
Sponsor
Novo Nordisk A/S
Obiettivo di iscrizione
60
Inizio
23 Oct 2020
Completamento stimato
03 Jun 2027

Di cosa tratta questo studio?

This study is about a medicine called Esperoct® (sometimes known as turoctocog alfa pegol or N8-GP). It's specifically for males who have haemophilia A. Haemophilia A is a condition where your blood doesn't clot properly, leading to easier bleeding. Esperoct® is a treatment given regularly to help prevent these bleeds.

The main goal of this study is to collect information over a long time – around 5 to 7 years – about how well Esperoct® works in preventing bleeds and whether it causes any side effects. Doctors want to understand its long-term effects in people using it as part of their regular treatment to prevent bleeds.

It's important to know that taking part in this study means you'll continue to get the same medical care and treatment as you usually would. The study is simply looking at how Esperoct® is used in real life. Your participation helps doctors learn more about this medicine to help others with haemophilia A in the future.

Punti chiave

  • This study is for males with haemophilia A who use Esperoct®.
  • It aims to understand Esperoct®'s long-term effectiveness and side effects.
  • Your treatment and medical care won't change if you join.
  • You'll share information about your bleeds and health over 5-7 years.
  • Participation is voluntary, and you can leave at any time without affecting your care.
  • Your involvement helps improve understanding of haemophilia A treatment.

Chi può essere idoneo?

This study is for males of any age who have been diagnosed with moderate or severe haemophilia A. You must already be using or be about to start using the regular preventive treatment, Esperoct®. The decision for you to use Esperoct® must have been made by you and your doctor independently, before you decide to join this study.

Before you can take part, you'll need to read and sign a consent form, showing you understand what's involved. This is a very important step to make sure you're comfortable with everything.

You cannot join the study if you've been in it before, or if you're allergic to Esperoct® or similar medicines. Also, if your doctor suspects you have 'inhibitors' (antibodies that stop the medicine from working) or if you have difficulty understanding the study information, you won't be able to participate.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you male?
  2. Do you have moderate or severe haemophilia A?
  3. Are you currently using or about to start using Esperoct® for regular prevention?
  4. Has the decision to use Esperoct® already been made by you and your doctor?
  5. Are you comfortable signing a consent form to participate?
  6. Do you understand the study information and feel able to cooperate?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to join this study, it means you'll continue with your usual medical appointments and treatment with Esperoct® as prescribed by your doctor. The study doesn't change your treatment plan. Your clinic visits will be just like your normal check-ups.

During these visits, the study doctor might ask you some questions about your health and if you've had any side effects since your last visit. They might also suggest some routine tests if they think it's helpful. You'll be asked to keep a simple diary at home, noting down any bleeds you have, how you treated them, and when you took your regular Esperoct® medicine.

Your participation in this study will last for quite a while, typically between 5 to 7 years, depending on when you start. You have the right to leave the study at any time, for any reason, and this decision will not affect your current or future medical care in any way.

Rischi e benefici potenziali

Taking part in this study won't change your medical care, so you'll continue to receive the same treatment you usually would. There aren't any extra medical procedures for the study, which means no additional medical risks. The main benefit is knowing you're helping medical experts learn more about how Esperoct® works over time, which can help other people with haemophilia A in the future. You always have the right to leave the study at any point, and your care will not be affected.

Locations (27)

  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Codice postale verificato
    Vienna, Austria
  • UMHAT "Tsaritsa Yoanna-ISUL"
    Codice postale verificato
    Sofia, Bulgaria
  • KBC Zagreb, Rebro, Hemofilija centar
    Codice postale verificato
    Zagabria, Croazia
  • FN Brno odd. hematologie
    Codice postale verificato
    Brno, Czechia
  • FN HK - IV. Interni hematologicka klinika
    Codice postale verificato
    Hradec Králové, Czechia
  • North Estonia Medical Centre Foundation
    Codice postale verificato
    Tallinn, Estonia
  • Tartu University Hospital Haematology Clinic
    Codice postale verificato
    Tartu, Estonia
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Codice postale verificato
    Berlino, Germania
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Codice postale verificato
    Bonn, Germania
  • "Laiko" General Hospital of Athens
    Codice postale verificato
    Athens, Greece
  • "Laiko" General Hospital of Athens
    Codice postale verificato
    Athens, Greece
  • Aghia Sophia Childrens' Hospital
    Codice postale verificato
    Athens, Greece

Domande comuni

What is Esperoct®?

Esperoct® is a medicine used to prevent bleeding in people with haemophilia A.

Do I have to do anything differently with my medicine if I join?

No, you will continue to take Esperoct® exactly as your doctor has prescribed; the study doesn't change your treatment.

Quanto durerà lo studio per me?

The study will last for about 5 to 7 years, depending on when you start.

Can I leave the study whenever I want?

Yes, you are free to leave the study at any time, for any reason, and it won't impact your medical care.

What information will I need to share?

You'll be asked about any bleeds and side effects, and to keep a diary of your bleeds and when you take your medicine.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A Study Following Males With Haemophilia A on Prophylaxis Wi…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.